The financials
Aktis Oncology, Inc. by the numbers
Aktis Oncology, Inc. (AKTS) reported revenue of $3.4M in Q2 2026 (quarter ended June 30, 2026), up 134% from the same quarter a year earlier. That came with net loss of $24M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.4M | $1.4M | +134% |
| Operating income | −$29M | −$18M | n/a |
| Net income | −$24M | −$15M | n/a |
| Diluted EPS | −$0.44 | −$18.60 | n/a |
Biotechnology
Ranks #52 of 145 by Smart Score